The 2023 Citeline Pharma Intelligence Awards Japan winners by category:
- Best New Drug – Sponsored by CMIC: Amvuttra, Alnylam
- Licensing Deal of the Year: TAK-279, Takeda
- Biotech Company of the Year – Sponsored by EPS Holdings: PeptiDream
- Best CRO/CDMO: A2 Healthcare
- Executive of the Year: Chris Cargill, Sosei Group
- Financing Deal of the Year: Chordia Therapeutics
- Pharma Company of the Year – Sponsored by Syneos Health: Takeda
- Lifetime Achievement Award – Sponsored by ICON: Joji Nakayama
Tokyo, Japan – Wednesday, October 18, 2023 – The much-anticipated Citeline Pharma Intelligence Awards Japan 2023 have concluded, shining a spotlight on the most exceptional advancements and innovations in the Japanese global life sciences industry. The glittering awards ceremony took place at the Palace Hotel in Tokyo, recognizing organizations and individuals whose groundbreaking work has had a significant impact on the biopharmaceutical landscape.
Over 200 leading innovators attended the prestigious event, which featured a diverse range of nominations, making it a challenging task for the panel of esteemed independent judges to select the winners. The Awards span eight categories, covering a spectrum of key biotech activities, advances in healthcare and innovation and personal achievement. The winners were selected based on their outstanding contributions to the life sciences industry, their commitment to innovation and their dedication to improving patient outcomes.
The Citeline Pharma Intelligence Awards Japan 2023 winners are as follows:
Best New Drug – Sponsored by CMIC: Amvuttra, Alnylam Japan
Amvuttra, indicated for a very serious, high-need disease, scored well based on the benefits of its siRNA technical platform, which allows improved stability, delivery and lower and less frequent dosing.
Licensing Deal of the Year: TAK-279, Takeda
Our panel of judges was impressed not only by the size of this deal but also that it provided a possibly best-in-class molecule as an important addition to the pipeline, in a promising mode of action with broad potential indications with large patient need.
Biotech Company of the Year – Sponsored by EPS Holdings: PeptiDream
Our winner in this category has gained attention for multiple big pharma deals that generate a stable income stream, driven by its productive technology platform. A solid pipeline and targeted acquisitions have further added to its success.
Best CRO & CDMO: A2 Healthcare
A2 Healthcare, which also has a presence in Taiwan as well as Japan, impressed our judges with its diversified offerings, strength in patient recruitment and initiatives to use electronic approaches to documentation.
Executive of the Year: Chris Cargill, Sosei Group
Cargill took this award for the second year in a row. Our judges were impressed by his rounded industry knowledge, strong financial background, clear strategy, leadership and delivery of deals and results.
Financing Deal of the Year: Chordia Therapeutics
Chordia was seen as doing well to raise substantial new funding from a broad range of investors in a generally challenging investment climate to ensure long-term financial stability. The investor interest also provided important validation of its business strategy and pipeline potential.
Pharma Company of the Year – Sponsored by Syneos Health: Takeda
A combination of a substantial landmark deal for a versatile novel drug for immune-mediated disorders, multiple other alliances and R&D progress in high-need areas, along with launches for a new vaccine for dengue, a solid financial performance and sustainability and global drug access programs, all contributed to Takeda’s win.
Lifetime Achievement Award – Sponsored by ICON: Joji Nakayama
Our winner stood out for many reasons, including his past role as the CEO of one of Japan’s leading pharma companies, which at the time was facing a number of major challenges. Several transformative acquisitions were made during his tenure, which supported a highly successful strategic pivot to oncology that subsequently paid off through large global partnerships for highly effective therapies.
Ian Haydock, Editor-in-Chief, APAC, said: "We are thrilled to announce the winners of the Citeline Pharma Intelligence Awards Japan 2023. This year's winners have demonstrated exceptional leadership and innovation in the field of life sciences. Their achievements not only advance the industry but also contribute to improving the lives of patients worldwide. We are already looking forward to 2024!”
Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory related decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. For more information on one of the world’s most trusted health science partners, visit Citeline.